Accreditation Information
Target Audience
This activity is intended for oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists engaged in the care of patients with breast cancer.
Learning Objectives
- Assess recent clinical trial data evaluating both currently approved and emerging therapies for the treatment of patients with HR+/HER2– breast cancer and its impact on the current standard of care
- Evaluate the safety and efficacy of currently available and potential future treatment options that are being examined in patients with triple-negative breast cancer
- Examine various patient- and disease-related factors that impact the selection of therapy for patients with HER2+ breast cancer in order to individually tailor care for each patient with this malignancy
- Develop strategies that encourage the multidisciplinary care of patients with all subtypes of breast cancer, including the role of the medical oncologist, surgeon, radiation oncologist, nurse, pharmacist, and advanced practitioner, in order to optimize patient outcomes
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive CME credit points, you MUST pass the posttest and complete the evaluation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
|
| |
|---|---|
|
Jagsi, Reshma, MD, DPhil
|
National Medical Advisor Panelist: Blue Cross Blue Shield
|
|
Kalinsky, Kevin, MD, MS, FASCO
|
Consultant, Advisor, Speaker: AstraZeneca, Bicycle Therapeutics, bioTheranostics, Daiichi Sankyo, Eli Lilly, Genentech (Roche), Gilead Sciences, Jazz Pharmaceuticals, Menarini Silicon Biosystems, Merck, Mersana Therapeutics, Myovant Sciences, Novartis, Pfizer, ProteinQure, Puma Biotechnology, RayzeBio, Regor Therapeutics, Relay Therapeutics, Seagen, Seattle Genetics (Seagen)
|
|
King, Tari Ann, MD, FACS, FSSO, FASCO
|
Consultant, Advisor, Speaker: Ataraxis AI, Daiichi Sankyo, Exact Sciences, Veracyte
|
|
Khan, Atif, MD, MS
|
Consultant, Advisor, Speaker: PreludeDx; Researcher: Merck, Varian
|
|
McArthur, Heather, MD, MPH, FASCO
|
Consultant, Advisor, Speaker: ALX, Arvinas, AstraZeneca, Boston Scientific, Celcuity, Daiichi Sankyo, Delcath, Genentech, Gilead, Lilly, Novartis, Pfizer
|
|
Modi, Shanu, MD
|
Consultant, Advisor, Speaker: AstraZeneca, BioNTech, Boehringer Ingelheim, BMS, D3 Bio, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, Macrogenics, Nuvation Bio, Pfizer, Seattle Genetics; Researcher: AstraZeneca, BioNTech, Boehringer Ingelheim, BMS, D3 Bio, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, Macrogenics, Nuvation Bio, Pfizer, Seattle Genetics
|
|
Morrow, Monica, MD, FACS
|
Has no relevant financial relationships
|
|
O’Regan, Ruth, MD
|
Consultant, Advisor, Speaker: Biotheranostics, Gilead, Puma, Lilly; Researcher: Novartis
|
Instructions for Credit
To receive CE credit, learners must follow these steps:
- Link for activity evaluation coming soon
- Complete the activity evaluation
- Upon completion of all evaluation questions, your credit will be made available for download immediately.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
To receive CE credit, learners must follow these steps:
- Accesss link for activity evaluation: https://cme.partnersed.com/AtlantaBreast2025
- Complete the activity evaluation
- Upon completion of all evaluation questions, your credit will be made available for download immediately.